

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION N	0.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/643,458	09/643,458 08/22/2000		Daniel T. Mytych	JB0976Q	9578
24265	7590	03/23/2004		EXAMINER	
		OUGH CORPORA	LI, BAO Q		
		TMENT (K-6-1, 19 G HILL ROAD	990)	ART UNIT	PAPER NUMBER
		NJ 07033-0530		1648	
				DATE MAILED: 03/23/200	14

Please find below and/or attached an Office communication concerning this application or proceeding.

$\mathbf{r} = \mathbf{r} + \mathbf{r}$						
	Application No.	Applicant(s)				
	09/643,458	MYTYCH ET AL.				
Office Action Summary	Examiner	Art Unit				
	Bao Qun Li	1648				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be ting within the statutory minimum of thirty (30) da will apply and will expire SIX (6) MONTHS from cause the application to become ABANDONI	mely filed ys will be considered timely. n the mailing date of this communication. ED (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on 23 De						
2a) This action is FINAL . 2b) This action is non-final.						
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4) Claim(s) 1-3,8,16,18 and 21-27 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) Claim(s) is/are allowed. 6) Claim(s) 1-3,8,16,18 and 21-27 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or election requirement.						
Application Papers						
9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
Attachment(s)						
1) Notice of References Cited (PTO-892)	4) Interview Summar					
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date 07/16/2001	Paper No(s)/Mail D	Patent Application (PTO-152)				

Application/Control Number: 09/643,458 Page 2

Art Unit: 1648

DETAILED ACTION

Amendment filed on paper No. 16 has been acknowledged. Claims 1, 8, 16 and 18 have been amended. Claims 4-7, 9-15, 17, 19 and 20 have been canceled. New claims 21-27 are added. Claims 1-3, 8, 16, 18 and 21-27 are pending.

Election/Restrictions

- 1. Applicant's election with traverse of Group II, claims 16, 18 and 21-22 in the scope of SEQ ID NO: 9, 12 and 15 in Paper No. 19 is acknowledged. The traversal is on the ground(s) that it would not constitute a serious burden to search all claims and all sequences as claimed. Applicants' argument has been fully considered, all claims are rejoined. However, searching all of sequences, as claims drafted constitute a serious burden. Therefore, claims 1-3, 8, 16, 18, 21 and 27 are considered in the scope of SEQ ID NO: 9, 12 and 15.
- 2. Applicants are reminded to amend the claims to the scope of SEQ ID NO: 9, 12 and 15 for reflecting the examination on the merits.

Sequence requirements

- 3. This application contains sequence disclosures in lines 10, and 15-19 of page No. 3 and in table 1 of page 17 that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.
- 4. Full compliance with the sequence rules is required in response to this Office Action. Please insert the sequence identification number (SEQ ID NO:) after each disclosed sequences. A complete response to this office action should include both compliance with the sequence rules and a response to the Office Action set forth below. Failure to fully comply with **both** these requirements in the time period set forth in this office action will be held non-responsive.

Claim Rejections - 35 USC § 112

5. The following is a quotation of the second paragraph of 35 U.S.C. 112:

Application/Control Number: 09/643,458 Page 3

Art Unit: 1648

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

6. Claims 16, 18 and 21-22 are rejected under 35 U.S.C. 112, second paragraph, as being incomplete for omitting essential steps, such omission amounting to a gap between the steps. See MPEP § 2172.01. The omitted steps are: immobilizing the peptide onto a solid phase. This is an essential step because the specification teaches that all assay need to immobilize the peptide onto a solid support (See lines 26-28 on page 12, lines 11 and 20 on page 13). This affects the dependent claims 21-22.

Conclusion

Claims 1-3, 8, 16, 18, 21 and 27 in the scope of SEQ ID NO: 9, 12 and 15 are free of art rejection. However, the application is not in the condition for allowance. Please amend the claims and specification to overcome the objection and rejection.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bao Qun Li whose telephone number is 571-272-0906. The examiner can normally be reached on 7:00 to 4:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Housel can be reached on 571-272-0902. The fax phone number for the organization where this application or proceeding is assigned is 571-272-1600.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Bao Oun Li

03/11/2004

SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600